Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide ... as well as death due to cardiovascular disease. Type 2 diabetes (T2D) patients with CKD will ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Jan 28 (Reuters) - The U.S. FDA has approved Novo ... in diabetes patients with chronic kidney disease (CKD), the Danish drugmaker said on Tuesday. Novo's blockbuster diabetes drug Ozempic belongs ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

The US Food and Drug ... Novo's request to add risk reduction for renal disease-related events to the Ozempic label. According to Novo Nordisk, over 40% of persons with type 2 diabetes have ...